Published in N Engl J Med on October 22, 2009
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy (2016) 7.05
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
Clan genomics and the complex architecture of human disease. Cell (2011) 4.53
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol (2013) 3.13
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology (2013) 2.64
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol (2015) 2.25
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Genetics of Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.96
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A (2011) 1.90
Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A (2011) 1.85
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
The link between the GBA gene and parkinsonism. Lancet Neurol (2012) 1.80
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord (2014) 1.76
Towards a complete resolution of the genetic architecture of disease. Trends Genet (2010) 1.75
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol (2015) 1.72
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain (2015) 1.71
Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med (2011) 1.71
The genetics of Parkinson disease. J Geriatr Psychiatry Neurol (2010) 1.69
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis (2010) 1.65
Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology (2015) 1.64
The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord (2013) 1.63
The function of α-synuclein. Neuron (2013) 1.63
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol (2010) 1.63
Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci (2012) 1.58
Exome sequencing: a transformative technology. Lancet Neurol (2011) 1.57
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain (2014) 1.54
Glucocerebrosidase is shaking up the synucleinopathies. Brain (2014) 1.50
False-positive results using a Gaucher diagnostic kit--RecTL and N370S. Mol Genet Metab (2010) 1.48
Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease. Brain (2015) 1.48
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A (2013) 1.45
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol (2011) 1.45
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem (2011) 1.42
Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet (2012) 1.41
Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet (2014) 1.40
Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease. Neurol Genet (2017) 1.40
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol (2014) 1.37
Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med Genet (2011) 1.36
Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab (2010) 1.35
Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. Cell Metab (2013) 1.32
Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med (2012) 1.30
The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep (2010) 1.28
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int (2012) 1.23
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis (2010) 1.21
Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease. PLoS One (2011) 1.19
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord (2012) 1.15
Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. J Med Chem (2012) 1.13
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord (2012) 1.13
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci Transl Med (2014) 1.11
Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol (2012) 1.10
A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Hum Mol Genet (2011) 1.10
iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep (2014) 1.08
Sphingolipid lysosomal storage disorders. Nature (2014) 1.08
Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab (2012) 1.08
Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol (2012) 1.08
Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol (2012) 1.07
Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics (2010) 1.06
Genetics and genomics of Parkinson's disease. Genome Med (2014) 1.04
Glucocerebrosidase and Parkinson disease: Recent advances. Mol Cell Neurosci (2015) 1.03
Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain (2014) 1.03
What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord (2014) 1.03
Genetics of Alzheimer's disease. Neurotherapeutics (2014) 1.02
Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Hum Mol Genet (2014) 1.02
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab (2011) 1.02
Animal models for Gaucher disease research. Dis Model Mech (2011) 1.02
The role of saposin C in Gaucher disease. Mol Genet Metab (2012) 1.02
The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain (2012) 1.01
Genetic variability at the PARK16 locus. Eur J Hum Genet (2010) 1.01
Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Couns (2013) 1.01
Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci U S A (2013) 1.01
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener (2010) 1.00
Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism Relat Disord (2011) 1.00
Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology (2010) 0.99
MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5. J Cell Biol (2015) 0.99
Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet (2013) 0.99
Perspective: Finding common ground. Nature (2016) 0.98
Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol (2012) 0.98
A novel common variant in DCST2 is associated with length in early life and height in adulthood. Hum Mol Genet (2014) 0.98
α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A (2016) 0.97
Genetics of Parkinson disease and essential tremor. Curr Opin Neurol (2010) 0.96
On estimating the relation between blood group and disease. Ann Hum Genet (1955) 26.39
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med (2004) 7.60
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology (2008) 3.83
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat (2008) 3.53
Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab (2004) 3.06
Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab (2004) 2.92
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology (2008) 2.73
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab (2003) 2.29
Parkinsonism among Gaucher disease carriers. J Med Genet (2004) 2.24
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab (2007) 2.21
Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord (2007) 2.12
Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: Pathogenic changes and "modifier" polymorphisms. Hum Mutat (2004) 2.07
Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol (2009) 2.06
Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res (1997) 2.06
Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol (2009) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol (2008) 1.89
The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol (2008) 1.87
Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. Am J Hum Genet (2003) 1.81
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology (2006) 1.79
Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab (2001) 1.74
Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord (2006) 1.72
Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J (2008) 1.68
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging (2007) 1.67
Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol (2007) 1.58
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett (2009) 1.56
Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol (1999) 1.49
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord (2008) 1.48
Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry (2007) 1.47
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis (2006) 1.34
Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol Dis (2006) 1.28
Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology (2009) 1.26
Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat Disord (2008) 1.24
The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord (2009) 1.10
The E326K mutation and Gaucher disease: mutation or polymorphism? Clin Genet (2002) 1.09
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
A genome-wide transcriptional analysis of the mitotic cell cycle. Mol Cell (1998) 19.67
Stat3 as an oncogene. Cell (1999) 17.39
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (1995) 15.20
In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell (1985) 11.63
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 11.59
The yeast nuclear pore complex: composition, architecture, and transport mechanism. J Cell Biol (2000) 10.20
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA (1998) 7.81
Positional cloning of the mouse circadian clock gene. Cell (1997) 7.79
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 7.10
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology (2006) 6.44
Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature (1999) 6.37
Three different genes in S. cerevisiae encode the catalytic subunits of the cAMP-dependent protein kinase. Cell (1987) 6.35
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 6.21
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med (2001) 6.07
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Virus-cell and cell-cell fusion. Annu Rev Cell Dev Biol (1996) 5.83
CARD15 mutations in Blau syndrome. Nat Genet (2001) 5.79
Functional identification of the mouse circadian Clock gene by transgenic BAC rescue. Cell (1997) 5.51
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Parkinson disease in twins: an etiologic study. JAMA (1999) 5.45
TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev (2001) 5.41
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell (2000) 5.31
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (2001) 5.24
Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet (1992) 5.12
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet (2000) 5.05
Cloning and characterization of BCY1, a locus encoding a regulatory subunit of the cyclic AMP-dependent protein kinase in Saccharomyces cerevisiae. Mol Cell Biol (1987) 5.03
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A (1997) 4.89
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet (1999) 4.74
The S. cerevisiae CDC25 gene product regulates the RAS/adenylate cyclase pathway. Cell (1987) 4.74
Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res (1997) 4.74
The fission yeast dis2+ gene required for chromosome disjoining encodes one of two putative type 1 protein phosphatases. Cell (1989) 4.72
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med (1996) 4.41
Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell (1998) 4.41
Phase-resolved optical coherence tomography and optical Doppler tomography for imaging blood flow in human skin with fast scanning speed and high velocity sensitivity. Opt Lett (2000) 4.33
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 4.13
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet (2000) 4.12
Analytical gel isotachophoresis of proteins with carrier ampholyte spacers. Ann N Y Acad Sci (1973) 4.09
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06
Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med (1993) 3.96
Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum Mol Genet (1999) 3.93
Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology (1995) 3.91
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature (1998) 3.86
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology (2008) 3.83
Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell (1998) 3.79
A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature (1992) 3.71
The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron (2001) 3.68
Location and primary structure of a major antigenic site for poliovirus neutralization. Nature (1983) 3.64
Unconventional myosins in inner-ear sensory epithelia. J Cell Biol (1997) 3.64
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology (2005) 3.57
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry (2000) 3.54
Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat (2002) 3.53
Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell (2001) 3.49
Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem (2000) 3.46
Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet (1994) 3.39
Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology (1995) 3.37
The Atf1 transcription factor is a target for the Sty1 stress-activated MAP kinase pathway in fission yeast. Genes Dev (1996) 3.36
IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology (2010) 3.34
Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell (2001) 3.29
Regulation of the fission yeast transcription factor Pap1 by oxidative stress: requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Spc1. Genes Dev (1998) 3.27
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Cold-sensitive nuclear division arrest mutants of the fission yeast Schizosaccharomyces pombe. J Mol Biol (1983) 3.22
Identification of the pleiotropic cell division cycle gene NDA2 as one of two different alpha-tubulin genes in Schizosaccharomyces pombe. Cell (1984) 3.22
Cloning and characterization of the high-affinity cAMP phosphodiesterase of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1986) 3.19
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
The JIP group of mitogen-activated protein kinase scaffold proteins. Mol Cell Biol (1999) 3.18
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet (2001) 3.15
Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science (1995) 3.15